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The increase in activity of centers with cardiac transplant programs has been limited 
because of the unavailability of high quality donor organs. Nonpulsatile coronary 
perfusion (NPCP) with hypothermia has allowed long-term cardiac preservation in 
various experimental models.1-4 This experiment was designed to study the effects of 
PGE1 in an experimental NPCP. 
 
 
 
MATERIALS AND METHODS 
 
Adult mongrel dogs weighing between 19 and 28 kg were anesthesized with 
phentobarbital (30 mg/kg IV). A right thoracotomy incision was made. The aorta was 
clamped and 250 mL of standard cardioplegic solution was administered. The heart 
was extracted, sectioning the aorta, pulmonary artery, vena cavas, and pulmonary 
veins at the level of its pericardial reflection. Once the heart was removed, it was 
connected to the NPCP. 
 
This system consists of a reservoir that contains the selected solution in which is added 
a mixture of O2 and CO2 in a 95:5 ratio through an 8-µm micropore filter. The heart 
was suspended from the aortic root to a cannula that connects to the reservoir and 
has an interphase chamber of air. The heart is introduced to another reservoir that 
allows the experiment to be performed under sterile conditions and also has the same 
solution at 4°C. A roller pump permits us to recover the solution from the lower 
reservoir. Two groups were formed according to the preservation solution employed: 
group 1 (n = 11): The composition of the solution is Na 140 mEq/L; Ca 3 mEq/L; Cl 129 
mEq/L; K 20 mEq/L; HCO3 12 mEq/L; glucose 4 g/L; lidocaine 0.5 g/L; chorpromazine 16 
mg/L; dextran 1.8%; osmolarity 380 mosm/L; PO2 600 to 800 mmHg; PCO2 25 to 30 
mmHg, perfusion pressure 25 to 35 cm H2O. 
 
The hearts were preserved in this system for 21 to 26 hours after which orthotopic 
heart transplants were performed in seven dogs. Before unclamping the aorta, a 
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reperfusion solution composed of lactated Ringer's + 6 mEq/L HCO3 + 16 mg/L 
chorpromazine + mannitol was infused. The experiment was concluded three hours 
after stopping extracorporeal circulation (ECC). In group 2, n = 10. PGE1 (100 µg/L) was 
added to the same solution used in group 1, preserving the heart for 21 to 26 hours, 
and performing orthotopic heart transplants in six cases. The studies performed during 
the preservation period were: (1) increase in heart weight; (2) serial acid-base 
equilibriums of the solution; (3) coronary resistance evolution, obtained by the 
quotient between pressure and flow of the solution; (4) glucose, CPK, K, from the 
coronary sinus and perfusion solution; (5) myocardial temperature; and (6) light and 
electron microscope studies. Cardiac function after the transplant was evaluated for: 
(1) possibility of suspending ECC; (2) cardiac rhythm; (3) need of inotropic agents; and 
(4) arterial pressure, right atrial and left atrial pressure, cardiac output, and pulmonary 
artery PO2. 
 
 
 
RESULTS 
 
The increase in weight of the hearts was between 28% to 39% in group 1 and between 
28% to 41% in group 2. In spite of this increase, the hearts were flaccid at palpation; 
the edema disappearing rapidly after stopping ECC. The average increase in coronary 
resistance at the end of the preservation period was 22 ± 9% in group 1, and 15 ± 6% in 
group 2 (P < .05). These results were correlated with the final coronary flow which was 
850 ± 250 mL/h in group 1 and 1,120 ± 270 mL/h in group 2. The evolution of the 
coronary flow and of CPK seems to us valid parameters to study the quality of 
preservation. Previously, 20 dogs were operated on to perfect the NPCP technique. In 
this preliminary series with perfusion defects, the increase in coronary resistance was 
82 ± 21% and the average CPK was 276 ± 72 µ/L at the end of the preservation period. 
The postorthotopic heart transplant results are shown in Tables 1 and 2. The period of 
preservation was between 21 and 26 hours. In four cases of group 1, the heart started 
to beat spontaneously and electrical defibrillation was necessary in the three 
remaining cases. In all cases of group 1 it was possible to end ECC, although in three 
cases it was necessary to give high doses of isoproterenol and dobutamine. In five of 
the six cases of group 2, the hearts beat spontaneously. In only one case was it 
necessary to administer dobutamine at a dose of 5 µg/kg/min. In the rest of the cases, 
isoproterenol was administered to obtain a mild chronotropic effect. 
 
 
 
DISCUSSION 
 
These results show that this system of NPCP along with other systems,1-4 can provide 
adequate long-term cardiac preservation. The simplification of this system is based on 
the concept that the heart at 4°C does not need high flow rates. It is the quality of 
perfusion and not only the hypothermia that is responsible for these results. As 
mentioned, in the preliminary series of 20 experiments, in which existed various 
irregularities in the perfusion techniques, the median increase in the coronary 
resistance was 82%. 
 
PGE1 has demonstrated to be a potent vasodilator in the systemic and coronary 
circulation.5,6 PGE1 was also reported to have cytoprotective effects due to lysosomal 
membrane stabilization.7,8 In our study, addition of PGE1 to the perfusion system 
reduced coronary resistance and CPK levels at the end of the preservation period. 
These results were well correlated with those after transplant, achieving better 
hemodynamic function and less need of inotropic agents in group 2. 
 
 
 
REFERENCES 
 
1. Wicomb W, Cooper DKC, Hassoulas J, et al: J Thorac Cardiovasc Surg 83: 133, 
1982 
2. Mendler N, Struck E, Sebening F: Transplant Proc 16:173, 1984 
3. Guerraty A, Bettez P, Beaudet RL, et al: Transplant Proc 16:156, 1984 
4. Toledo-Pereyra LH: J Surg Res 30:181, 1981 
5. Carlson LA, Eriksson L: Lancet 1:155, 1973 
6. Bloor CM, White FC, Sobel BE: Cardiovasc Res 7:156, 1973 
7. Raflo GT, Wangensteen SL, Glenn TM, et al: Eur J Pharmacol 28:86, 1973 
8. Ogletree ML, Lefer AM: Circ Res 42:218, 1978 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Results After Orthotopic Heart Transplant (Group 1) 
No. 
Preservation 
(hours) 
Weight % Defibrillation 
Cardiac 
Rhythm 
Inotropic 
PA PO2 
mm Hg 
CO 
1 24 30 — SR ISO 0.2 >35  
2 21 28 — SR DOB 7 >33 1'5 to 2 
3 25 39 + SR ISO 0.2 >35 >2 
4 24 32 — NR ISO 0.3 30 to 35 — 
    
 
 DOB 5   
5 26 25 — SR ISO 1 25 to 28 1'4 
     DOB 15   
6 23 28 + NR ISO 0.4 28 to 32 — 
7 22 31 + NR ISO 0.4 >35 >2 
Abbreviations: PA PO2, pulmonary artery P02; CO, cardiac output L/min;                  
ISO, isoproterenol (µg/min); DOB, dobutamine (ug/kg/min); SR, sinus rhythm;        
NR, nodal rhythm. 
 
 
 
Table 2. Results After Orthotopic Heart Transplant (Group 2) 
No. 
Preservation 
(hours) 
Weight % Defibrillation 
Cardiac 
Rhythm 
Inotropic 
PA PO2 
mm Hg 
CO 
1 25 35 — SR ISO 0.1 >35 >2 
2 23 27 — SR ISO 0.3 >35 >2 
3 26 41 — NR ISO 0.3 30 to 35 — 
     DOB 5   
4 24 30 + SR ISO 0.4 30 to 33 1'5 to 2 
5 25 35 — SR ISO 0.2 >33 >2 
6 21 28 — SR — >35 — 
Abbreviations: PA PO2, pulmonary artery P02; CO, cardiac output L/min;                  
ISO, isoproterenol (µg/min); DOB, dobutamine (ug/kg/min); SR, sinus rhythm;        
NR, nodal rhythm. 
 
